<i>In utero</i> exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers

Viganò, Alessandra; Mora, Stefano; Giacomet, Vania; Stucchi, Sara; Manfredini, Valeria; Gabiano, Clara; Salvini, Filippo; Cellini, Monica; Tamburrini, Enrica; Puzzovio, Maria; Zuccotti, Gian Vincenzo

doi:10.3851/imp1909

Cited by 62 publications

(40 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the Registry also receives and evaluates all retrospective (spontaneous) case reports as well (for signal generation), and has received no signal indicating issues with bone development. This is in keeping with additional data in children born to HIV-infected women that have not shown effects on growth or bone development at 1-5 years of age [37,38], though one study did show slightly lower length for age but not weight for age at 1 year despite equal incidence of low birth weight and size in children born to women taking TDF [39].…”

Section: Discussionmentioning

confidence: 51%

Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry

Brown

Verna

Pereira

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 51%

Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry

Brown

Verna

Pereira

et al. 2012

Journal of Hepatology

View full text Add to dashboard Cite

“…A study comparing the growth of infants born to HIV-positive mothers who were treated with tenofovir during pregnancy with those whose mothers were not treated with tenofovir found no difference in infant growth between the two groups 33. Growth was measured through weight and height at birth and after 12 months 33. Exposure to tenofovir was in utero only, that is, mothers were not allowed to breast feed 33.…”

Section: Hbv Treatment Considerations In Women Of Childbearing Agementioning

confidence: 99%

Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders

Visvanathan

Dusheiko

Giles

et al. 2015

Gut

View full text Add to dashboard Cite

Hepatitis B during pregnancy presents unique management issues for both the mother and fetus. These include the lack of a current cohesive strategy for treatment and follow-up of mothers and their babies; the uncertain risk of postpartum HBV flares; the lack of randomised trial data on the safety and efficacy of antiviral treatment in pregnancy; the lack of head-to-head studies comparing different antivirals in pregnancy; and the lack of epidemiologic information regarding infection across different populations globally. This position paper provides a comprehensive review of the management of women with HBV infection prior to conception, throughout each stage of pregnancy and postpartum, as well as recommendations and clinical approaches for the follow-up of children born to infected mothers, based on available evidence in the literature and recommendations from international experts. Prevention of perinatal transmission is an important component of global efforts to reduce the burden of chronic HBV since vertical transmission is responsible for most of the chronic infection worldwide.

show abstract

“…There are limited human data on the effect of in utero exposure to tenofovir and bone health. A case series of 15 children with intrauterine tenofovir exposure found normal growth at 1 year on 14/15 children [15], and a small multicenter observational study found no evidence of impaired growth after a median follow-up of 23 months [16]. The largest observational data on tenofovir in pregnancy to date originates from the US Pediatric HIV/AIDS Cohort Study (PHACS).…”

Section: Before Conceptionmentioning

confidence: 97%

Management of HBV in Pregnancy

Kelly¹,

Peters²

2015

Curr Hepatology Rep

View full text Add to dashboard Cite

Hepatitis B in pregnancy must include diagnosis and management of the pregnant woman as well as modalities to decrease mother to child transmission (MTCT). MTCT remains the most important mode of hepatitis B virus (HBV) transmission, although effective strategies exist to reduce this risk. Universal screening for HBV can identify women with previously unrecognized infection and allow for targeted therapy to prevent MTCT. All children of HBV-infected mothers should receive passive active immunoprophylaxis with hepatitis B immune globulin (HBIG) and HBV vaccination within 12 h of birth. With such measures, the risk of transmission can be decreased to less than 1 % in women with low viral loads. Immunoprophylaxis failures occur in as many as 15 % of children born to mothers with high viral loads at the time of delivery (>6 log copies/ml or >200,000 IU/ml), and therefore, additional treatment in the third trimester is warranted in this group. Antiviral therapy with lamivudine, tenofovir, or telbivudine in the third trimester can decrease MTCT to less than 5 % and should be used in women with high viral loads in the third trimester. Postpartum flares of liver disease are common, and therefore, careful monitoring is warranted in women who stop therapy. The decision to breastfeed while on antiviral therapy should be individualized, but current evidence suggests that it is safe.

show abstract

In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers

Abstract: Exposure to TDF during pregnancy does not impair growth patterns, bone health and markers of bone metabolism in SR infants and young children born to HIV-infected women.

Cited by 62 publications

References 20 publications

Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry

Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry

Managing HBV in pregnancy. Prevention, prophylaxis, treatment and follow-up: position paper produced by Australian, UK and New Zealand key opinion leaders

Management of HBV in Pregnancy

Contact Info

Product

Resources

About